FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898480566> ?p ?o ?g. }

• W2898480566 endingPage "viii453" @default.
• W2898480566 startingPage "viii453" @default.
• W2898480566 abstract "Background: The IL-2 inducible kinase (ITK) is highly expressed in metastatic melanomas and molecular targeting and/or pharmacologic inhibition of ITK in preclinical melanoma models suppresses cell proliferation without inducing cell death (Carson CCR 2015). Ibrutinib suppresses proliferation of melanoma cell lines in low nM concentrations (Moschos ASCO 2017, TPS9592). We hypothesize that targeting DMCM with ibrutinib will induce antitumor responses, especially in high ITK-expressing melanomas. Methods: This is an open-label, single-arm, Simon’s 2-stage design, multicenter, phase II study for patients (pts) with DMCM refractory to or ineligible for PD-1 and MAPK inhibitors, if BRAFV600-mutant. Given that the IC50 of ibrutinib for ITK is > 10 times than Bruton’s tyrosine kinase’s, we administered ibrutinib at 840mg qd. We hypothesized that an ineffective drug will have a = <5% response rate and = <18% 6-month PFS rate. We present the results of the first stage. Results: 18 pts (13 males; median age 63.5, range 37-82; 14 with M1c disease; 4 with BRAFV600 mutation; 12 with performance status 1 or 2; 4 with resistance to 4 treatments; 5 with resistance to = >5 treatments) were enrolled. Median exposure to ibrutinib was 27.5 days (range 4-155). The most frequent all-grade side effects were fatigue (55%), anorexia (50%), gastrointestinal upset (44%), and anemia (39%). 4 grade IV (hyponatremia, sepsis, cytokine release syndrome, and constipation occurred 6% each) and 9 grade III events [hyponatremia (17%); pneumonia, hypertension, anemia, hypoalbuminemia, dehydration, lymphopenia occurred 6% each] were seen. No antitumor responses were seen. At a median follow-up of 5 months, all pts had progressed (median PFS was 1.3 months, range 0.2-5.5). 15 pts were discontinued from study due to progression and 14 pts had died from melanoma. Median OS was 5 months (range 0.3-10.4 months) in pts who died. Conclusions: In this treatment-refractory DMCM, high-dose ibrutinib did not induce any meaningful clinical benefit; therefore the study will not proceed to stage 2. Correlation between PFS and expression of ITK by melanoma cells and density of tumor-infiltrating T- and B-cells in pretreatment tumor specimens will be reported at the time of the meeting. Clinical trial identification: NCT03427398. Legal entity responsible for the study: NCI-CTEP. Funding: NCI-CTEP, Pharmacyclics. Disclosure: All authors have declared no conflicts of interest." @default.
• W2898480566 created "2018-11-02" @default.
• W2898480566 creator A5001015275 @default.
• W2898480566 creator A5010552772 @default.
• W2898480566 creator A5012965017 @default.
• W2898480566 creator A5017025756 @default.
• W2898480566 creator A5018121293 @default.
• W2898480566 creator A5018642666 @default.
• W2898480566 creator A5025872938 @default.
• W2898480566 creator A5045110376 @default.
• W2898480566 creator A5046203056 @default.
• W2898480566 creator A5049066352 @default.
• W2898480566 creator A5058902095 @default.
• W2898480566 creator A5069589993 @default.
• W2898480566 creator A5077389338 @default.
• W2898480566 creator A5079370474 @default.
• W2898480566 creator A5080536692 @default.
• W2898480566 creator A5080736692 @default.
• W2898480566 creator A5087376683 @default.
• W2898480566 creator A5088476385 @default.
• W2898480566 date "2018-10-01" @default.
• W2898480566 modified "2023-09-27" @default.
• W2898480566 title "NCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM)" @default.
• W2898480566 doi "https://doi.org/10.1093/annonc/mdy289.024" @default.
• W2898480566 hasPublicationYear "2018" @default.
• W2898480566 type Work @default.
• W2898480566 sameAs 2898480566 @default.
• W2898480566 citedByCount "0" @default.
• W2898480566 crossrefType "journal-article" @default.
• W2898480566 hasAuthorship W2898480566A5001015275 @default.
• W2898480566 hasAuthorship W2898480566A5010552772 @default.
• W2898480566 hasAuthorship W2898480566A5012965017 @default.
• W2898480566 hasAuthorship W2898480566A5017025756 @default.
• W2898480566 hasAuthorship W2898480566A5018121293 @default.
• W2898480566 hasAuthorship W2898480566A5018642666 @default.
• W2898480566 hasAuthorship W2898480566A5025872938 @default.
• W2898480566 hasAuthorship W2898480566A5045110376 @default.
• W2898480566 hasAuthorship W2898480566A5046203056 @default.
• W2898480566 hasAuthorship W2898480566A5049066352 @default.
• W2898480566 hasAuthorship W2898480566A5058902095 @default.
• W2898480566 hasAuthorship W2898480566A5069589993 @default.
• W2898480566 hasAuthorship W2898480566A5077389338 @default.
• W2898480566 hasAuthorship W2898480566A5079370474 @default.
• W2898480566 hasAuthorship W2898480566A5080536692 @default.
• W2898480566 hasAuthorship W2898480566A5080736692 @default.
• W2898480566 hasAuthorship W2898480566A5087376683 @default.
• W2898480566 hasAuthorship W2898480566A5088476385 @default.
• W2898480566 hasBestOaLocation W28984805661 @default.
• W2898480566 hasConcept C126322002 @default.
• W2898480566 hasConcept C143998085 @default.
• W2898480566 hasConcept C2777938653 @default.
• W2898480566 hasConcept C2778461978 @default.
• W2898480566 hasConcept C2779878957 @default.
• W2898480566 hasConcept C71924100 @default.
• W2898480566 hasConcept C90924648 @default.
• W2898480566 hasConcept C98274493 @default.
• W2898480566 hasConceptScore W2898480566C126322002 @default.
• W2898480566 hasConceptScore W2898480566C143998085 @default.
• W2898480566 hasConceptScore W2898480566C2777938653 @default.
• W2898480566 hasConceptScore W2898480566C2778461978 @default.
• W2898480566 hasConceptScore W2898480566C2779878957 @default.
• W2898480566 hasConceptScore W2898480566C71924100 @default.
• W2898480566 hasConceptScore W2898480566C90924648 @default.
• W2898480566 hasConceptScore W2898480566C98274493 @default.
• W2898480566 hasLocation W28984805661 @default.
• W2898480566 hasOpenAccess W2898480566 @default.
• W2898480566 hasPrimaryLocation W28984805661 @default.
• W2898480566 hasRelatedWork W1935657689 @default.
• W2898480566 hasRelatedWork W2740451692 @default.
• W2898480566 hasRelatedWork W2902590192 @default.
• W2898480566 hasRelatedWork W2979826161 @default.
• W2898480566 hasRelatedWork W2982026813 @default.
• W2898480566 hasRelatedWork W3016795150 @default.
• W2898480566 hasRelatedWork W3164413398 @default.
• W2898480566 hasRelatedWork W3213393646 @default.
• W2898480566 hasRelatedWork W4291227654 @default.
• W2898480566 hasRelatedWork W4308687399 @default.
• W2898480566 hasVolume "29" @default.
• W2898480566 isParatext "false" @default.
• W2898480566 isRetracted "false" @default.
• W2898480566 magId "2898480566" @default.
• W2898480566 workType "article" @default.